vs
Apellis Pharmaceuticals, Inc.（APLS）与FIRSTSUN CAPITAL BANCORP（FSUN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是FIRSTSUN CAPITAL BANCORP的1.8倍（$199.9M vs $110.0M），FIRSTSUN CAPITAL BANCORP净利率更高（19.6% vs -29.5%，领先49.1%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
FirstSun Capital Bancorp是一家总部位于美国的金融控股公司，提供商业及个人贷款、存款产品、财富管理、财资解决方案等全面的银行金融服务，主要面向美国区域市场的个人消费者、中小企业及企业客户。
APLS vs FSUN — 直观对比
营收规模更大
APLS
是对方的1.8倍
$110.0M
净利率更高
FSUN
高出49.1%
-29.5%
两年增速更快
APLS
近两年复合增速
6.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $110.0M |
| 净利润 | $-59.0M | $21.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 19.6% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | -8.4% |
| 每股收益（稀释后） | $-0.40 | $0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFSUN
| Q1 26 | — | $110.0M | ||
| Q4 25 | $199.9M | $110.2M | ||
| Q3 25 | $458.6M | $107.3M | ||
| Q2 25 | $178.5M | $105.6M | ||
| Q1 25 | $166.8M | $96.2M | ||
| Q4 24 | $212.5M | $98.7M | ||
| Q3 24 | $196.8M | $98.2M | ||
| Q2 24 | $199.7M | $96.2M |
净利润APLSFSUN
| Q1 26 | — | $21.6M | ||
| Q4 25 | $-59.0M | $24.8M | ||
| Q3 25 | $215.7M | $23.2M | ||
| Q2 25 | $-42.2M | $26.4M | ||
| Q1 25 | $-92.2M | $23.6M | ||
| Q4 24 | $-36.4M | $16.4M | ||
| Q3 24 | $-57.4M | $22.4M | ||
| Q2 24 | $-37.7M | $24.6M |
营业利润率APLSFSUN
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 29.0% | ||
| Q3 25 | 48.7% | 26.4% | ||
| Q2 25 | -18.6% | 31.2% | ||
| Q1 25 | -50.0% | 30.9% | ||
| Q4 24 | -12.3% | 20.4% | ||
| Q3 24 | -24.0% | 29.1% | ||
| Q2 24 | -14.7% | 32.3% |
净利率APLSFSUN
| Q1 26 | — | 19.6% | ||
| Q4 25 | -29.5% | 22.5% | ||
| Q3 25 | 47.0% | 21.6% | ||
| Q2 25 | -23.6% | 25.0% | ||
| Q1 25 | -55.3% | 24.5% | ||
| Q4 24 | -17.1% | 16.6% | ||
| Q3 24 | -29.2% | 22.8% | ||
| Q2 24 | -18.9% | 25.5% |
每股收益（稀释后）APLSFSUN
| Q1 26 | — | $0.76 | ||
| Q4 25 | $-0.40 | $0.89 | ||
| Q3 25 | $1.67 | $0.82 | ||
| Q2 25 | $-0.33 | $0.93 | ||
| Q1 25 | $-0.74 | $0.83 | ||
| Q4 24 | $-0.30 | $0.57 | ||
| Q3 24 | $-0.46 | $0.79 | ||
| Q2 24 | $-0.30 | $0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $413.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.2B |
| 总资产 | $1.1B | $8.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFSUN
| Q1 26 | — | $413.7M | ||
| Q4 25 | $466.2M | $652.6M | ||
| Q3 25 | $479.2M | $659.9M | ||
| Q2 25 | $370.0M | $785.1M | ||
| Q1 25 | $358.4M | $621.4M | ||
| Q4 24 | $411.3M | $615.9M | ||
| Q3 24 | $396.9M | $573.7M | ||
| Q2 24 | $360.1M | $535.8M |
股东权益APLSFSUN
| Q1 26 | — | $1.2B | ||
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.0B | ||
| Q3 24 | $237.1M | $1.0B | ||
| Q2 24 | $264.3M | $996.6M |
总资产APLSFSUN
| Q1 26 | — | $8.6B | ||
| Q4 25 | $1.1B | $8.5B | ||
| Q3 25 | $1.1B | $8.5B | ||
| Q2 25 | $821.4M | $8.4B | ||
| Q1 25 | $807.3M | $8.2B | ||
| Q4 24 | $885.1M | $8.1B | ||
| Q3 24 | $901.9M | $8.1B | ||
| Q2 24 | $904.5M | $8.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSFSUN
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $111.5M | ||
| Q3 25 | $108.5M | $49.4M | ||
| Q2 25 | $4.4M | $15.0M | ||
| Q1 25 | $-53.4M | $26.4M | ||
| Q4 24 | $19.4M | $101.1M | ||
| Q3 24 | $34.1M | $48.1M | ||
| Q2 24 | $-8.3M | $20.9M |
自由现金流APLSFSUN
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $104.0M | ||
| Q3 25 | $108.3M | $47.6M | ||
| Q2 25 | $4.4M | $13.0M | ||
| Q1 25 | $-53.4M | $24.3M | ||
| Q4 24 | $19.3M | $95.7M | ||
| Q3 24 | — | $47.1M | ||
| Q2 24 | $-8.4M | $19.9M |
自由现金流率APLSFSUN
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 94.3% | ||
| Q3 25 | 23.6% | 44.4% | ||
| Q2 25 | 2.5% | 12.3% | ||
| Q1 25 | -32.0% | 25.3% | ||
| Q4 24 | 9.1% | 97.0% | ||
| Q3 24 | — | 47.9% | ||
| Q2 24 | -4.2% | 20.6% |
资本支出强度APLSFSUN
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 6.8% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | 5.5% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 1.1% |
现金转化率APLSFSUN
| Q1 26 | — | — | ||
| Q4 25 | — | 4.49× | ||
| Q3 25 | 0.50× | 2.13× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 6.18× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | 0.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
